Monday, December 2, 2013

Cell Therapeutics Gets $5M In Milestone Payment

Seattle-based Cell Therapeutics said this morning that it has received $5M, via a milestone payment from Teva Pharmaceutical Industrires. Cell Therapeutics said the pament was related to the achievement of a sales milestone for TRISENOX, which it sold to Cephalon, which was acquired by Teva. Cell Therapeutics said it is eligible to receive an additional $95M in milestone payments related to sales and development milestones for that compound.